Shionogi Presents Phase 2/3 Clinical Trial Results
Post# of 1418
(Total Views: 249)
Posted On: 03/24/2022 10:43:24 AM
Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622 - February, 7, 2022
Clinical symptom improvement:
S-217622 showed a tendency toward improvement in total score of 12 COVID-19 symptoms
Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan - February, 25, 2022
Clinical symptom improvement:
・ No significant difference in the time-weighted average change in the total score of 12 COVID-19 symptoms from initiation of administration up to 120 hours while they changed in the direction of improvement (primary endpoint not achieved)
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622 - March 3, 2022
FDA has cleared the IND for S-217622
SHIONOGI & CO., LTD.
Fiscal 2021 3Q Conference Call
February 1, 2022
"As shown on page 12, there was a significant difference in the amount of change from baseline in titer, which can be thought of as viral activity, on day four in both dose groups.
Significant decrease can be seen also in the placebo group on day six. Unfortunately, the difference is not significant , but the trend is still going on"
I'll sum it up for you while you go find the links if you want to do your own DD in your investment or thinking of investing.
They took the easy path like Pfizer with mild to moderate Covid infected participants which is way different than Todos that took the hard road with severe hospitalized patients.
Even with outpatients, they only had a small trial...
"placebo-controlled, double-blind study in 428 SARS-CoV-2 infected subjects with mild/moderate symptoms (419 in Japan and 9 in South Korea)"
but, but Todos had way less. Yeah BECAUSE it was a trial with hospitalized patients. That's how it goes.
If you are asymptomatic or mild, you'd probably try anything including a glass of milk and warm blanket. When you are on your death bed, completely different story.
No significant improvement in symptoms
No significant difference in titers on day 6 vs the placebo group
but they were able to partner with ACTG and get an IND. Think about that with those results.
Oh, and this isn't the company I'm talking about with one product in clinical trials (i.e. Phase I) valued at almost 1/2 billion
Clinical symptom improvement:
S-217622 showed a tendency toward improvement in total score of 12 COVID-19 symptoms
Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan - February, 25, 2022
Clinical symptom improvement:
・ No significant difference in the time-weighted average change in the total score of 12 COVID-19 symptoms from initiation of administration up to 120 hours while they changed in the direction of improvement (primary endpoint not achieved)
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622 - March 3, 2022
FDA has cleared the IND for S-217622
SHIONOGI & CO., LTD.
Fiscal 2021 3Q Conference Call
February 1, 2022
"As shown on page 12, there was a significant difference in the amount of change from baseline in titer, which can be thought of as viral activity, on day four in both dose groups.
Significant decrease can be seen also in the placebo group on day six. Unfortunately, the difference is not significant , but the trend is still going on"
I'll sum it up for you while you go find the links if you want to do your own DD in your investment or thinking of investing.
They took the easy path like Pfizer with mild to moderate Covid infected participants which is way different than Todos that took the hard road with severe hospitalized patients.
Even with outpatients, they only had a small trial...
"placebo-controlled, double-blind study in 428 SARS-CoV-2 infected subjects with mild/moderate symptoms (419 in Japan and 9 in South Korea)"
but, but Todos had way less. Yeah BECAUSE it was a trial with hospitalized patients. That's how it goes.
If you are asymptomatic or mild, you'd probably try anything including a glass of milk and warm blanket. When you are on your death bed, completely different story.
No significant improvement in symptoms
No significant difference in titers on day 6 vs the placebo group
but they were able to partner with ACTG and get an IND. Think about that with those results.
Oh, and this isn't the company I'm talking about with one product in clinical trials (i.e. Phase I) valued at almost 1/2 billion
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼